MedPointe/Sepracor Astelin Copromotion Deal Adds 450 Reps To Allergy Drug
Executive Summary
Sepracor will use its 450-person Xopenex sales force to detail MedPointe's Astelin under a copromotion agreement for the antihistamine
You may also be interested in...
Sepracor Soltara “not approvable”
Sepracor's NDA for allergic rhinitisproduct Soltara (tecastemizole) deemed "not approvable" March 6. FDA wants additional assurance that there is no potential for QTc prolongation with the product. FDA also raised issues related to phospholipidosis and cardiomyopathy observed in animal safety studies. The Soltara NDA was submitted March 9, 2001. Soltara is a metabolite of Janssen's Hismanal (astemizole), which was removed from the market in 1999 due to cardiac side effects...
Sepracor Xopenex Expanded Sales Force Will Focus on Managed Care
Sepracor will increase its Xopenex sales force by 350 reps as a part of a reorganizational shift to focus on managed care and Medicare.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011